- Home
- RARE vs KGS Comparison
RARE vs KGS Comparison
Compare RARE & KGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- KGS
- Stock Information
- Founded
- RARE 2010
- KGS 2011
- Country
- RARE United States
- KGS United States
- Employees
- RARE N/A
- KGS N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- KGS
- Sector
- RARE Health Care
- KGS
- Exchange
- RARE Nasdaq
- KGS Nasdaq
- Market Cap
- RARE 3.5B
- KGS 3.0B
- IPO Year
- RARE 2014
- KGS 2023
- Fundamental
- Price
- RARE $36.68
- KGS $34.34
- Analyst Decision
- RARE Strong Buy
- KGS Strong Buy
- Analyst Count
- RARE 15
- KGS 10
- Target Price
- RARE $90.53
- KGS $41.20
- AVG Volume (30 Days)
- RARE 1.1M
- KGS 1.0M
- Earning Date
- RARE 07-31-2025
- KGS 08-11-2025
- Dividend Yield
- RARE N/A
- KGS 5.28%
- EPS Growth
- RARE N/A
- KGS N/A
- EPS
- RARE N/A
- KGS 0.54
- Revenue
- RARE $590,689,000.00
- KGS $1,273,461,000.00
- Revenue This Year
- RARE $18.94
- KGS $17.66
- Revenue Next Year
- RARE $28.93
- KGS $6.52
- P/E Ratio
- RARE N/A
- KGS $63.30
- Revenue Growth
- RARE 33.46
- KGS 45.41
- 52 Week Low
- RARE $29.59
- KGS $24.84
- 52 Week High
- RARE $60.37
- KGS $50.43
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- KGS 46.98
- Support Level
- RARE $36.03
- KGS $33.61
- Resistance Level
- RARE $37.74
- KGS $35.08
- Average True Range (ATR)
- RARE 1.46
- KGS 1.10
- MACD
- RARE -0.01
- KGS -0.05
- Stochastic Oscillator
- RARE 26.56
- KGS 23.02
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About KGS Kodiak Gas Services Inc.
Kodiak Gas Services Inc is an operator of contract compression infrastructure in the United States. It manages business through two operating segments namely Contract Services and Other Services. Contract Services consists of operating Company-owned and customer-owned compression, and gas treating and cooling infrastructure, pursuant to primarily fixed-revenue contracts to enable the production and gathering of natural gas and oil. Other Services consist of a full range of contract services to support the ancillary needs of customers, including station construction, maintenance and overhaul, freight and crane charges, and other time and material-based offerings.